内科領域におけるbalofloxacinの臨床的検討  [in Japanese] Clinical study on balofloxacin  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

新キノロンカルボン酸系の合成抗菌薬balofloxacinを9例の呼吸器感染症患者に投与し臨床的検討を行った。臨床効果は, 3例は感染症状不明確のため除外し, 6例について判定した。<BR>1) 呼吸器感染症に対する臨床効果は, 有効6例, 有効率100%であった。<BR>2) 細菌学的効果は3例で原因菌が分離され, <I>Haemophilus influenzae</I> 1株は消失, 2株の<I>Staphylococcus aureus</I>は消失1例, 判定不能1例であった。<BR>3) 本薬投与による副作用は1例で下痢・腹痛がみられ, 臨床検査値の異常は好酸球数の増加, GPTの上昇がそれぞれ1例であった。

The clinical efficacy and safety of balofloxacin (BLFX), a new quinolone derivative, were evaluated during the treatment of 9 patients with respiratory tract infections.<BR>1) The clinical efficacy of BLFX in the treatment of respiratory tract infections was judged as good in 6 patients.<BR>2) In the bacteriological study, causative organisms were isolated from 3 patients: one strain of<I>Haemophilus influenzae</I> was eradicated, and 1 strain of <I>Staphylococcus aureus</I> was eradicated.<BR>3) Diarrhea and abdominal pain were observed in one patient as adverse reactions. Eosinophilia was observed in one patient and a transient elevation of GPT was seen in another patient.

Journal

  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 43, 512-514, 1995-11-27

    Japanese Society of Chemotherapy

References:  5

Codes

Page Top